Onset of action of escitalopram compared with other antidepressants: Results of a pooled analysis

International Clinical Psychopharmacology

Volumn 21, Issue 2, 2006, Pages 105-110

  Kasper, Siegfried ^a   Spadone, Christian ^b   Verpillat, Patrice ^c   Angst, Jules ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b SAINT LOUIS HOSPITAL   (France)

^c Lundbeck   (France)

^d UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

Antidepressants; Early onset of effect; Escitalopram; Pooled analysis; SSRIs

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMATIC REVIEW; CONTROLLED CLINICAL TRIAL; DEPRESSION; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TIME;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 33645234727     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000194375.42589.c3     Document Type: Article

References (30)

1. Alexopoulos GS, Privitera W, Ventura D, Bose A, Lenz SM, Wang Q (2004). Fixed dose of escitalopram (10 mg/day) and a flexible dosing regimen of sertraline (50-200 mg/day) in a randomised, double-blind comparison in depressed patients. (Abstract from poster 6257 presented at the International Congress of Biological Psychiatry, February 9-13 2004; Sydney, Australia). World J Biol Psychiatry 5(Suppl 1):97.
2. Auquier P, Robitail S, Llorca P-M, Rive B (2003). Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 7:259-268.
3. Bech P, Tanghøj P, Cialdella P, Andersen HF, Pedersen AG (2004). Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 7:283-290.
4. Bielski RJ, Ventura D, Chang C-C (2004). A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65:1190-1196.
5. Blier P (2003). The pharmacology of putative early onset antidepressant strategies. Eur Neuropsychopharmacol 13:57-66.
6. Burke WJ, Gergel I, Bose A (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336.
7. Colonna L, Reines EH, Andersen HF (2005). A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive patients with major depressive disorder. Curr Med Res Opin 21:1659-1668.
8. Culpepper L (2001). Early onset of antidepressant action: impact on primary care. J Clin Psychiatry 62(Suppl 4):4-6.
9. Forest Laboratories (2000). Flexible dose comparison of the safety and efficacy of Lu 26-054, citalopram, and placebo in the treatment of major depressive disorder. Report No. SCT-MD-02. Data on file.
10. Frazer A, Gerhardt GA, Daws LC (1999). New views of biogenic amine transporter function: implications for neuropsychopharmacology. Int J Neuropsychopharmacol 2:305-320.
11. Gorman JM, Korotzer A, Su G (2002). Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 7(Suppl 4):40-44.
12. Guy W (1976). ECDEU assessment manual for psychopharmacology, rev. edn. Rockville, Maryland: US National Institute of Health.
13. Kasper S, de Swart H, Andersen HF (2005). Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 13:884-891.
14. Leon AC (2001). Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J Clin Psychiatry 62(Suppl 4):12-16.
15. Lepola UM, Loft H, Reines EH (2003). Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int J Neuropsychopharmacol 18:211-217.
16. Lepola U, Wade A, Andersen HF (2004). Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 19:149-155.
17. Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, et al. (2005). Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 30:445-460.
18. Montgomery SA (1997). Fast-onset antidepressants. Int Clin Psychopharmacol 12(Suppl 3):S1-S5.
19. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
20. Montgomery SA, Bech P, Blier P, Möller HJ, Nierenberg AA, Pinder RM, et al. (2002). Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 63:694-699.
21. Montgomery SA, Huusom AKT, Bothmer J (2004). A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50:57-64.
22. Norman TR, Leonard BE (1994). Fast-acting antidepressants. Can the need be met? CNS Drugs 2:120-131.
23. Posternak MA, Zimmerman M (2005). Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 66:148-158.
24. Rosenbaum JF (2001). Introduction: early onset of antidepressant action. J Clin Psychiatry 62(Suppl 4):3.
25. Stahl SM, Nierenberg AA, Gorman JM (2001). Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 62(Suppl 4):17-23.
26. Stassen HH, Angst J, Delini-Stula A (1994). Severity of baseline and onset of improvement in depression: metanalysis of imipramine and moclobemide versus placebo. Eur Psychiatry 9:129-136.
27. Stassen HH, Angst J, Delini-Stula A (1997a). Onset of action under antidepressant treatment. Eur Psychiatry 12:163-165.
28. Stassen HH, Angst J, Delini-Stula A (1997b). Delayed onset of action of antidepressant drugs? Survey of recent results. Eur Psychiatry 12:166-176.
29. Thase ME (2001). Methodology to measure onset of action. J Clin Psychiatry 62(Suppl 15):18-21.
30. Wade A, Lemming OM, Bang H, Hedepaard K (2002). Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17:95-102.